

REFERENCES (FIRST AND LAST PAGES)

1. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet* 2005; 366: 1925-34.
2. Allie DE, Hebert CJ, Lirtzman MD, et al. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. *Eurointervention* 2005; 1(1): 60-69.
3. Hallett JW, Byrne J, Gayari MM, et al. Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. *J Vasc Surg* 1997; 25: 29-38.
4. Allie DE. The global impact of CLI in 2006. "The Rutherford Class VII patient." Presentation at Multidisciplinary International CLI Summit 2006, Nov 2; New Orleans, LA.
5. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. [Internet]. Available at <http://www.hcup.ahrq.gov/>
6. Yost ML. Peripheral arterial disease underestimated, underdiagnosed and undertreated. Volume II: A significant opportunity for interventional therapies. Atlanta (GA): THE SAGE GROUP; 2004.
7. McIntyre KE. Aortoiliac occlusive disease. Continuing Medical Education (CME) article on the e-medicine website. [Cited 2002]. Available at <http://www.emedicine.com/med/topic2759.htm>
8. Gray BH. Endovascular treatment of peripheral arterial disease. *J Am Osteopath Assoc*. 2000; 100(10 Su Pt 2): S15-20.
9. White CJ. Selecting the appropriate interventional procedure: who benefits from treatment? Presentation at Special Session VI: Peripheral arterial disease: what is new? (Nov 11). American Heart Association Scientific Sessions 2003, Nov 9-12; Orlando, Florida.
10. Ramee SR. Primer of iliac, femoral and renal intervention: what you need to know! Presentation at Fellows Course 2003, April 12. Archived in Expert Slide Presentations on the Transcatheter Cardiovascular Therapeutics (TCT) TCTMD website. [Cited 2003]. Available at Available at <http://www.tctmd.com/>.
11. TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of peripheral arterial disease. *J Vasc Surg* 2000; 31(suppl): S1-288.

38. Bosiers M, Deloose K, Verbist J, Peeters P. Nitinol stenting for treatment of "below-the-knee" critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation. *J Cardiovasc Surg (Torino)*. 2007; 48(4):455-61.
39. Ansel GM. Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease. *Catheter Cardiovasc Interv*. 2007; 69(6):886-9.
40. SFA Stenting Studies. *Endovascular Today* 2007; 6(6): 66.
41. Scheinert DS, Biamino G, Schmidt AJ. Preliminary experience with DESs in Tibial Arteries. *Endovascular Today* 2006; 5(7): 60-2.
42. Bosiers M, Deloose K, Verbist J, Peeters P. First clinical application of absorbable metal stents in the treatment of critical limb ischemia: 12-month results. *Vascular Disease Management* 2005; 2(4): 86-91.
43. Fischer M, Schwabe C, Schulte KL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. *J Endovasc Ther*. 2006; 13(3):281-90.
44. Kickuth R, Keo HH, Triller J, Ludwig K, Do DD. Initial clinical experience with the 4-F self-expanding XPERT stent system for infrapopliteal treatment of patients with severe claudication and critical limb ischemia. *J Vasc Interv Radiol*. 2007; 18(6):703-8.
45. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. *J Endovasc Ther*. 2007; 14(2):241-50.
46. Smouse HB. Drug-eluting stents in the periphery. A summary of barriers, unanswered questions, and potential benefits of this technology. *Endovascular Today* 2007; 6(6): 72-74.
47. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. *J Am Coll Cardiol* 2005; 45: 312-5.
48. Yost ML. Peripheral arterial disease. Endovascular market analysis by vascular territory. Atlanta (GA): THE SAGE GROUP; 2006.
49. Yost ML. Acute limb ischemia. A market of multiple therapies and multiple procedures. Atlanta (GA): THE SAGE GROUP; 2005.